Utility of Neutrophil-to-Lymphocyte Ratio for Predicting Malignancy Risk and Prognosis in Patients with Dermatomyositis.
Malignancy-associated dermatomyositis (MADM) is a well-accepted disorder1 . However, since only a subset of dermatomyositis (DM) patients will have/develop malignancy, the risk/benefit ratio of malignancy screening for all DM patients is controversial. Clinical clues suggesting malignancy presence/development could help identify at-risk DM patients that warrant malignancy screening. Furthermore, clinical clues in MADM patients that can predict prognosis could help guide treatment strategies.